Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Issue 3 (26th July 2020)

• Record Type: Journal Article
• Authors: Kloosterboer, Sanne Maartje; de Winter, Brenda C.M.; Reichart, Catrien G.; Kouijzer, Mirjam E.J.; de Kroon, Matthias M.J.; van Daalen, Emma; Ester, Wietske A.; Rieken, Rob; Dieleman, Gwen C.; van Altena, Daphne; Bartelds, Beatrijs; van Schaik, Ron H.N.; Nasserinejad, Kazem; Hillegers, Manon H.J.; van Gelder, Teun; Dierckx, Bram; Koch, Birgit C.P.
• Is Part Of: British journal of clinical pharmacology. Volume 87:Issue 3(2021)
• Page Start: 1069
• Page End: 1081
• Publication Date: 2020-07-26
• Subjects: adolescent -- antipsychotic -- autism spectrum disorder -- body mass index -- child -- cytochrome P‐450 -- drug monitoring -- prolactin -- risperidone -- weight gain; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14465
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aim: Risperidone is the most commonly prescribed antipsychotic drug to children and adolescents worldwide, but it is associated with serious side effects, including weight gain. This study assessed the relationship of risperidone and 9‐hydroxyrisperidone trough concentrations, maximum concentrations and 24‐hour area under the curves (AUCs) with body mass index (BMI) z ‐scores in children and adolescents with autism spectrum disorder (ASD) and behavioural problems. Secondary outcomes were metabolic, endocrine, extrapyramidal and cardiac side effects and effectiveness. Methods: Forty‐two children and adolescents (32 males) aged 6‐18 years were included in a 24‐week prospective observational trial. Drug plasma concentrations, side effects and effectiveness were measured at several time points during follow‐up. Relevant pharmacokinetic covariates, including medication adherence and CYP2D6, CYP3A4, CYP3A5 and P‐glycoprotein ( ABCB1 ) genotypes, were measured. Nonlinear mixed‐effects modelling (NONMEM®) was used for a population pharmacokinetic analysis with 205 risperidone and 205 9‐hydroxyrisperidone concentrations. Subsequently, model‐based trough concentrations, maximum concentrations and 24‐hour AUCs were analysed to predict outcomes using generalized and linear mixed‐effects models. Results: A risperidone two‐compartment model combined with a 9‐hydroxyrisperidone one‐compartment model best described the measured concentrations. Of all the pharmacokinetic parameters, higher risperidone sum trough concentrations best predicted higher BMI z ‐scores during follow‐up ( P < .001). Higher sum trough concentrations also predicted more sedation ( P < .05), higher prolactin levels ( P < .001) and more effectiveness measured with Aberrant Behavior Checklist irritability score ( P < .01). Conclusion: Our results indicate a therapeutic window exists, which suggests that therapeutic drug monitoring of risperidone might increase safety and effectiveness in children and adolescents with ASD and behavioural problems.